Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Dat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Becaris Publishing Limited,
2023-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_2e68b7b1092c4873bb523cd37838a9af | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yanni Hao |e author |
| 700 | 1 | 0 | |a Wei-Chun Hsu |e author |
| 700 | 1 | 0 | |a Craig S Parzynski |e author |
| 700 | 1 | 0 | |a Evgeny Degtyarev |e author |
| 700 | 1 | 0 | |a Lisa V Hampson |e author |
| 700 | 1 | 0 | |a Aisha Masood |e author |
| 700 | 1 | 0 | |a Wen-Hsing Wu |e author |
| 245 | 0 | 0 | |a Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma |
| 260 | |b Becaris Publishing Limited, |c 2023-06-01T00:00:00Z. | ||
| 500 | |a 10.57264/cer-2022-0173 | ||
| 500 | |a 2042-6313 | ||
| 520 | |a Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Database. Results: Complete response rate was 69.1 versus 17.7% and the overall response rate was 85.6 versus 58.1% in tisagenlecleucel versus SoC, post weighting by odds. For overall survival, an estimated reduction in the risk of death was observed in favor of tisagenlecleucel over SoC. The hazard ratio for progressionfree survival was 0.45 (95% CI: 0.26, 0.88), and for time-to-next treatment was 0.34 (95% CI: 0.15, 0.78) with tisagenlecleucel versus SoC. Conclusion: A consistent trend toward improved efficacy end points was observed in favor of tisagenlecleucel versus SoC. | ||
| 546 | |a EN | ||
| 690 | |a anti-cd20 | ||
| 690 | |a car-t | ||
| 690 | |a follicular lymphoma | ||
| 690 | |a non-hodgkin lymphoma | ||
| 690 | |a real-world evidence | ||
| 690 | |a refractory | ||
| 690 | |a relapsed | ||
| 690 | |a standard of care | ||
| 690 | |a tisagenlecleucel | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Comparative Effectiveness Research, Vol 12, Iss 7 (2023) | |
| 787 | 0 | |n https://doaj.org/toc/2042-6313 | |
| 856 | 4 | 1 | |u https://doaj.org/article/2e68b7b1092c4873bb523cd37838a9af |z Connect to this object online. |